Rubric raises stake to 29.1M HRTX shares and takes preferred plus $35M notes
Rhea-AI Filing Summary
Heron Therapeutics insider transaction and financing. Rubric Capital Management LP and David Rosen acquired 2,387,225 shares of Heron Therapeutics common stock at $1.50 per share on 08/08/2025, increasing the Rubric Vehicles' indirect beneficial ownership to 29,100,728 shares. The filing shows the same group subscribed for $35,000,000 of Convertible Senior Unsecured Promissory Notes bearing cash interest at 5.0% per year and convertible at an initial rate of 555.5556 shares per $1,000 principal, subject to adjustment.
Rubric also received 94,610 Series A Convertible Preferred Shares, which convert into 946,100 common shares at an initial conversion price of $1.50 upon required stockholder approval under Nasdaq rules. The Notes become convertible after required stockholder approval or December 31, 2025 and mature on the fifth anniversary of the closing scheduled for August 12, 2025. Rubric and Mr. Rosen disclaim beneficial ownership except to the extent of pecuniary interest.
Positive
- $35,000,000 of convertible notes subscribed, providing immediate financing to the company
- Purchase of 2,387,225 common shares at $1.50 increases Rubric Vehicles' indirect holdings to 29,100,728 shares
- Issuance includes 94,610 Series A Convertible Preferred Shares that convert to 946,100 common shares at an initial conversion price of $1.50, aligning investor and company interests
Negative
- Conversion of Notes and Preferred Shares is contingent on stockholder approval under Nasdaq rules, delaying and making dilution conditional
- Convertible structure could lead to significant dilution if conversions are settled in shares rather than cash
- Notes include a provision allowing interest to be paid in new notes at 7.0% if deferred, increasing long-term cost
Insights
TL;DR: Rubric provided immediate capital and increased its stake materially, combining equity and $35M convertible financing.
The combination of an equity purchase of 2,387,225 shares at $1.50 and a $35,000,000 convertible note subscription represents a substantive infusion of capital into Heron Therapeutics. The notes carry a 5.0% cash coupon and a conversion formula explicitly stated (555.5556 shares per $1,000), creating a potential issuance of equity upon conversion that could materially increase share count depending on settlement choices and approval mechanics. The presence of preferred shares that convert into common stock at $1.50 further indicates layered financing with built-in conversion economics.
TL;DR: Conversion and settlement depend on Nasdaq shareholder approvals, creating conditional dilution and governance considerations.
The securities are convertible only after the company obtains the requisite stockholder approvals under Nasdaq rules or after December 31, 2025, meaning the intended equity conversion is contingent on a shareholder vote. That contingency delays automatic dilution until approvals are obtained and introduces a governance step that could influence timing and structure of any equity settlement. Rubric's disclaimer of beneficial ownership except for pecuniary interest is standard, but investors should note the indirect ownership concentration reported.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Purchase | Convertible Senior Unsecured Promissory Notes ("Notes") | 0 | $33,250,000.00 | -- |
| Purchase | Series A Convertible Preferred Stock ("Preferred Shares") | 94,610 | $15.00 | $1.42M |
| Purchase | Common Stock, par value $0.01 per share ("Common Stock") | 2,387,225 | $1.50 | $3.58M |
Footnotes (1)
- This Form 4 is filed by Rubric Capital Management LP ("Rubric Capital") and Mr. David Rosen, with respect to the securities held by certain funds and/or accounts (collectively, the "Rubric Vehicles"). Rubric Capital serves as the investment adviser to the Rubric Vehicles. Mr. David Rosen serves as the Managing Member of Rubric Capital Management GP, LLC, the general partner of Rubric Capital. The filing of this statement shall not be deemed an admission that any Reporting Person is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Act of 1934, as amended, or otherwise. Each Reporting Person expressly disclaims beneficial ownership of the securities reported herein except to the extent of its or his pecuniary interest therein. The Notes convert at an initial conversion rate of 555.5556 per $1,000 principal amount of Notes, subject to adjustment as set forth in that certain Note Purchase Agreement, dated as of August 8, 2025, by and between the Company, the purchasers from time to time party hereto, and Rubric Capital Management LP, as agent for the purchasers. Conversions of the Notes are settled, at the election of the Company, in cash, shares of Common Stock, or a combination of cash and shares of Common Stock. The Notes bear cash interest at a rate of 5.0% per year until maturity, provided that the Company has the right to pay all accrued and unpaid interest prior to September 1, 2026 in new Notes at a rate of 7.0% per year. The Notes are convertible after the later of (i) the receipt by the Company of the approval of its stockholders under the rules of the Nasdaq Capital Market of the issuance by the Company of all of shares of Common Stock upon conversion thereof (assuming settlement of conversions solely in Common Stock) without giving effect to any cap on conversion or (ii) December 31, 2025. The Notes mature on the fifth anniversary of the closing date, scheduled to occur on August 12, 2025. Upon receipt of the requisite votes of the Company's stockholders required to approve the issuance of the shares of Common Stock upon conversion of the Preferred Stock pursuant to the applicable rules of the Nasdaq Capital Market, the Preferred Shares shall, without any further action on the part of the holder thereof or the Company, automatically be converted at an initial conversion price of $1.50, subject to adjustment as set forth in the Certificate of Designation of Rights, Preferences and Privileges of the Preferred Shares, dated as of August 8, 2025.
